Navidea Biopharmaceuticals (NAVB) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Navidea Biopharmaceuticals (NAVB) Files $100M Mixed Shelf; 3.17M Common for Shareholders
May 9, 2014 8:23 AM EDTNavidea Biopharmaceuticals (AMEX: NAVB) filed a registration with the U.S. SEC to sell, from time to time, up to $100 million of Common Stock, Preferred Stock, Warrants, Subscription Rights, Purchase Contracts, Units, or any combination thereof.
The company also filed to sell up... More
